[{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"90dfa8a7-38cc-4b86-83f1-504cb26c394f","acronym":"LCI-HEM-PCNSL-RMPV-001","url":"https://clinicaltrials.gov/study/NCT04022980","created_at":"2021-01-18T19:45:06.884Z","updated_at":"2025-02-25T14:28:31.029Z","phase":"Phase 1","brief_title":"Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma","source_id_and_acronym":"NCT04022980 - LCI-HEM-PCNSL-RMPV-001","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 03/31/2020","start_date":" 03/31/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-13"},{"id":"8e23dfed-66db-4dea-b013-38aff34edc35","acronym":"NCI-2015-00960","url":"https://clinicaltrials.gov/study/NCT02427620","created_at":"2021-01-17T17:51:13.234Z","updated_at":"2024-07-02T16:34:36.739Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02427620 - NCI-2015-00960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-10"},{"id":"86dc7e81-ec59-452b-a3ee-1c37d19391d6","acronym":"NCI-2019-03188","url":"https://clinicaltrials.gov/study/NCT03970096","created_at":"2021-01-18T19:31:38.073Z","updated_at":"2024-07-02T16:35:00.086Z","phase":"Phase 2","brief_title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03970096 - NCI-2019-03188","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-05-30"},{"id":"970ea094-a661-4898-85eb-a557dddaf167","acronym":"","url":"https://clinicaltrials.gov/study/NCT01979536","created_at":"2021-01-18T09:00:59.609Z","updated_at":"2024-07-02T16:35:06.864Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT01979536","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • dexamethasone • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2024-04-30"},{"id":"14d4a3a9-74c5-4fe7-9c56-d7f4ac283b48","acronym":"NCI-2018-01752","url":"https://clinicaltrials.gov/study/NCT03779854","created_at":"2021-01-18T18:41:45.312Z","updated_at":"2024-07-02T16:35:12.968Z","phase":"Phase 2","brief_title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT03779854 - NCI-2018-01752","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-25"},{"id":"0255f9f7-4ccc-4e57-b819-91bcf2a8d85f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01858740","created_at":"2021-01-18T08:18:31.451Z","updated_at":"2024-07-02T16:35:15.236Z","phase":"Phase 2","brief_title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children","source_id_and_acronym":"NCT01858740","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • thiotepa • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/10/2014","start_date":" 04/10/2014","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-03-12"},{"id":"b84fa649-6a21-4a69-88fb-39a7bfebf3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02422641","created_at":"2021-01-18T11:35:12.764Z","updated_at":"2024-07-02T16:35:19.750Z","phase":"Phase 2","brief_title":"Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis","source_id_and_acronym":"NCT02422641","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-12"},{"id":"f09c4527-3f0d-4cac-ac7a-d781b123ac75","acronym":"","url":"https://clinicaltrials.gov/study/NCT02220985","created_at":"2021-01-18T10:24:33.980Z","updated_at":"2024-07-02T16:35:20.153Z","phase":"Phase 2","brief_title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","source_id_and_acronym":"NCT02220985","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate • fludarabine IV • thiotepa • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 02/03/2015","start_date":" 02/03/2015","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-02-08"},{"id":"d5be950f-3675-484f-9cf0-33481c11c95d","acronym":"NCI-2011-03562","url":"https://clinicaltrials.gov/study/NCT01527149","created_at":"2021-01-18T06:26:25.305Z","updated_at":"2024-07-02T16:35:20.370Z","phase":"Phase 2","brief_title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01527149 - NCI-2011-03562","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2011","start_date":" 12/06/2011","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-07"},{"id":"f300739e-1f9e-42ac-8361-e1fbf968624a","acronym":"PhALLCON","url":"https://clinicaltrials.gov/study/NCT03589326","created_at":"2021-01-18T17:39:06.668Z","updated_at":"2024-07-02T16:35:31.409Z","phase":"Phase 3","brief_title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03589326 - PhALLCON","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • Iclusig (ponatinib) • vincristine • prednisone • dexamethasone • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 08/12/2022","primary_completion_date":" 08/12/2022","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-10-27"},{"id":"eba29365-719c-4084-a482-6d1de994a799","acronym":"COG-ACNS0334","url":"https://clinicaltrials.gov/study/NCT00336024","created_at":"2021-01-18T01:09:40.733Z","updated_at":"2024-07-02T16:35:35.818Z","phase":"Phase 3","brief_title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","source_id_and_acronym":"NCT00336024 - COG-ACNS0334","lead_sponsor":"Children's Oncology Group","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cyclophosphamide • etoposide IV • methotrexate • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 08/06/2007","start_date":" 08/06/2007","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-09-25"},{"id":"a4c2ebb0-b6de-4797-9fa4-06a37d8a44b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122081","created_at":"2021-01-18T09:49:45.733Z","updated_at":"2024-07-02T16:35:36.447Z","phase":"Phase 1","brief_title":"Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT02122081","lead_sponsor":"Sumithira Vasu","biomarkers":" CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C","pipe":" | ","alterations":" NCAM1 positive","tags":["CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/27/2015","start_date":" 07/27/2015","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2023-09-21"},{"id":"20d2383a-ae5c-429a-a889-50e462e666a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951885","created_at":"2021-01-18T08:51:05.801Z","updated_at":"2024-07-02T16:35:37.507Z","phase":"Phase 3","brief_title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","source_id_and_acronym":"NCT01951885","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 07/07/2014","start_date":" 07/07/2014","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 08/11/2021","study_completion_date":" 08/11/2021","last_update_posted":"2023-09-11"},{"id":"0c094526-6b1e-4e8d-b65c-6feabab8a313","acronym":"ANGLeD","url":"https://clinicaltrials.gov/study/NCT03613181","created_at":"2021-01-18T17:45:29.869Z","updated_at":"2024-07-02T16:35:49.783Z","phase":"Phase 3","brief_title":"ANG1005 in Leptomeningeal Disease From Breast Cancer","source_id_and_acronym":"NCT03613181 - ANGLeD","lead_sponsor":"Angiochem Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Halaven (eribulin mesylate) • methotrexate IV • paclitaxel trevatide (ANG1005)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-24"},{"id":"01d7872c-62e6-480f-8138-2caec3d153a4","acronym":"METHOGLU","url":"https://clinicaltrials.gov/study/NCT05135858","created_at":"2021-11-26T14:53:40.439Z","updated_at":"2024-07-02T16:36:01.882Z","phase":"Phase 1","brief_title":"Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma","source_id_and_acronym":"NCT05135858 - METHOGLU","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2022-10-25"},{"id":"d61a1176-c8c9-41a5-bd71-59f92eb07fc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01168219","created_at":"2021-01-18T04:39:31.023Z","updated_at":"2024-07-02T16:36:06.057Z","phase":"Phase 2","brief_title":"Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01168219","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • methotrexate • fludarabine IV • busulfan • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 07/15/2010","start_date":" 07/15/2010","primary_txt":" Primary completion: 11/14/2015","primary_completion_date":" 11/14/2015","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2022-08-04"},{"id":"ca8c8218-ef0e-4b3f-81db-cfe6152d9968","acronym":"","url":"https://clinicaltrials.gov/study/NCT01412879","created_at":"2021-01-18T05:48:53.738Z","updated_at":"2024-07-02T16:36:22.101Z","phase":"Phase 2","brief_title":"S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01412879","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD20 • CCND1 • CD34","pipe":"","alterations":" ","tags":["CD20 • CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • dexamethasone • bendamustine • leucovorin calcium • melphalan • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2021-10-29"},{"id":"d1582dd1-e768-4f7e-b5d2-a0089b8a5d93","acronym":"","url":"https://clinicaltrials.gov/study/NCT00919503","created_at":"2021-01-18T03:33:26.727Z","updated_at":"2024-07-02T16:36:26.391Z","phase":"Phase 2","brief_title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","source_id_and_acronym":"NCT00919503","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 07/31/2009","start_date":" 07/31/2009","primary_txt":" Primary completion: 06/10/2020","primary_completion_date":" 06/10/2020","study_txt":" Completion: 06/10/2020","study_completion_date":" 06/10/2020","last_update_posted":"2021-08-13"},{"id":"68f83ef2-b454-4e39-b176-4027e828c89d","acronym":"NCI-2018-01302","url":"https://clinicaltrials.gov/study/NCT03602898","created_at":"2021-01-18T17:42:45.778Z","updated_at":"2024-07-02T16:36:28.451Z","phase":"Phase 2","brief_title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT03602898 - NCI-2018-01302","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" FLT3 • KMT2A • HLA-DRB1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate • fludarabine IV • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 09/17/2023","primary_completion_date":" 09/17/2023","study_txt":" Completion: 09/17/2023","study_completion_date":" 09/17/2023","last_update_posted":"2021-06-30"},{"id":"1611432e-6e0a-4cd7-b5b1-2ffab38012c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00860574","created_at":"2021-01-18T03:16:53.510Z","updated_at":"2025-02-25T16:23:06.732Z","phase":"Phase 2","brief_title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00860574","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2021-06-22"}]